<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://emdrive.echothis.com/index.php?action=history&amp;feed=atom&amp;title=MedlinePlus_Drug_Information.</id>
	<title>MedlinePlus Drug Information. - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://emdrive.echothis.com/index.php?action=history&amp;feed=atom&amp;title=MedlinePlus_Drug_Information."/>
	<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;action=history"/>
	<updated>2026-09-11T09:42:10Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.41.1</generator>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=455956&amp;oldid=prev</id>
		<title>Bryce56A860 at 10:42, 22 August 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=455956&amp;oldid=prev"/>
		<updated>2024-08-22T10:42:43Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 03:42, 22 August 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Tell your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider &lt;/del&gt;right away if you (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/del&gt;): &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;may &lt;/del&gt;not be &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;seeing &lt;/del&gt;as well as &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;before &lt;/del&gt;starting SABRIL; start to trip, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;bump into points&lt;/del&gt;, or are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a lot &lt;/del&gt;more awkward than &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;typical &lt;/del&gt;[https://www.&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;protopage&lt;/del&gt;.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ossidyrd9j Bookmarks&lt;/del&gt;]; are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;amazed &lt;/del&gt;by &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;individuals &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;points &lt;/del&gt;coming in front of you that seem to find out of no place; or if your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child &lt;/del&gt;is acting differently than typical.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The Vigabatrin REMS Program &lt;/del&gt;is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;required by the FDA to ensure educated risk-benefit decisions before initiating therapy, &lt;/del&gt;and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to ensure appropriate use vigabatrin while clients are treated. It is &lt;/del&gt;not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;possible for your healthcare provider &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;understand when &lt;/del&gt;vision loss &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;will occur&lt;/del&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;It is advised that your doctor examination your (or your child's) vision before or within 4 weeks after starting &lt;/del&gt;SABRIL &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;and at least every &lt;/del&gt;3 &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;months throughout therapy until SABRIL &lt;/del&gt;is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;stopped&lt;/del&gt;. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If &lt;/del&gt;you &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or your kid &lt;/del&gt;have any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;type &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;side effect that troubles you or that does not go away, tell your health care provider&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell &lt;/del&gt;your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider immediately &lt;/del&gt;if seizures &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;get worse&lt;/del&gt;. You and your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor &lt;/del&gt;will have to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;determine &lt;/del&gt;if you &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;need to &lt;/del&gt;take SABRIL while you are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;expectant&lt;/del&gt;. One of the most &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;common &lt;/del&gt;side effects of SABRIL in grownups consist of: blurred vision, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;drowsiness&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;wooziness&lt;/del&gt;, problems strolling or really feeling unskillful, drinking (tremor), and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;exhaustion&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Tell your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor &lt;/ins&gt;right away if you (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kid&lt;/ins&gt;): &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;could &lt;/ins&gt;not be &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;viewing &lt;/ins&gt;as well as &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;prior to &lt;/ins&gt;starting SABRIL; start to trip, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;run across things&lt;/ins&gt;, or are more awkward than &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;common &lt;/ins&gt;[https://www.&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;symbaloo&lt;/ins&gt;.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;embed/shared/AAAAAlJv5XsAA41_HzbcyQ== Rems product list&lt;/ins&gt;]; are &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;stunned &lt;/ins&gt;by &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;things &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;people &lt;/ins&gt;coming in front of you that seem to find out of no place; or if your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;infant &lt;/ins&gt;is acting differently than typical.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SABRIL (vigabatrin) &lt;/ins&gt;is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a prescription medication utilized with various other treatments in youngsters and adults 2 years old &lt;/ins&gt;and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;older with refractory complicated partial seizures (CPS) that have &lt;/ins&gt;not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;responded all right &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;several various other therapies and if the feasible advantages exceed the risk of &lt;/ins&gt;vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The most usual negative effects of &lt;/ins&gt;SABRIL &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;in youngsters &lt;/ins&gt;3 &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to 16 years &lt;/ins&gt;is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;weight gain&lt;/ins&gt;. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;With extreme vision loss, &lt;/ins&gt;you &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;may only &lt;/ins&gt;have &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;the ability to see points straight before you (in some cases called tunnel vision&quot;). You are at threat for vision loss with &lt;/ins&gt;any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;quantity &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SABRIL&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform &lt;/ins&gt;your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor today &lt;/ins&gt;if seizures &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;worsen&lt;/ins&gt;. You and your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider &lt;/ins&gt;will &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;certainly &lt;/ins&gt;have to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;decide &lt;/ins&gt;if you &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;should &lt;/ins&gt;take SABRIL while you are &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;pregnant&lt;/ins&gt;. One of the most &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;typical &lt;/ins&gt;side effects of SABRIL in grownups consist of: blurred vision, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;sleepiness&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;lightheadedness&lt;/ins&gt;, problems strolling or really feeling unskillful, drinking (tremor), and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;fatigue&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Bryce56A860</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=194196&amp;oldid=prev</id>
		<title>EmoryCarr4 at 23:59, 19 July 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=194196&amp;oldid=prev"/>
		<updated>2024-07-19T23:59:44Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 16:59, 19 July 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Tell your healthcare provider right &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;now &lt;/del&gt;if you (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/del&gt;): &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;might &lt;/del&gt;not be seeing as well as &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;prior to beginning &lt;/del&gt;SABRIL; start to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;journey&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;run across &lt;/del&gt;points, or are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;much &lt;/del&gt;more &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;clumsy &lt;/del&gt;than &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;usual &lt;/del&gt;[https://www.protopage.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;farrynco6b &lt;/del&gt;Bookmarks]; are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;shocked &lt;/del&gt;by individuals or points &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;being available &lt;/del&gt;in front of you that &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;appear ahead &lt;/del&gt;out of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nowhere&lt;/del&gt;; or if your child is acting &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;in a different way &lt;/del&gt;than typical.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SABRIL (&lt;/del&gt;vigabatrin&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;) &lt;/del&gt;is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a prescription medicine utilized with various other therapies in children and adults 2 years of age and older with refractory complicated partial seizures (CPS) who have &lt;/del&gt;not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;responded well enough &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a number of various other treatments and if the possible benefits surpass the threat of &lt;/del&gt;vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;It is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;suggested &lt;/del&gt;that your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider test &lt;/del&gt;your (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kid&lt;/del&gt;'s) vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;prior to &lt;/del&gt;or within 4 weeks after &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;beginning &lt;/del&gt;SABRIL and at &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;the very &lt;/del&gt;least every 3 months &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;during &lt;/del&gt;therapy &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;till &lt;/del&gt;SABRIL is stopped. If you or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster &lt;/del&gt;have any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kind &lt;/del&gt;of side &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;impact &lt;/del&gt;that &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;bothers &lt;/del&gt;you or that does not go away, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;inform &lt;/del&gt;your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare service &lt;/del&gt;provider.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform &lt;/del&gt;your healthcare provider if &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;you are expecting or intend to obtain pregnant&lt;/del&gt;. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If vision screening can not be done, &lt;/del&gt;your doctor &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;might proceed recommending SABRIL, yet &lt;/del&gt;will &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;certainly not &lt;/del&gt;have the &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ability to watch for any type &lt;/del&gt;of vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;loss. If vision examinations are refrained from doing consistently&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;your doctor might quit suggesting SABRIL for you &lt;/del&gt;(&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or your youngster&lt;/del&gt;).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Tell your healthcare provider right &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;away &lt;/ins&gt;if you (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/ins&gt;): &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;may &lt;/ins&gt;not be seeing as well as &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;before starting &lt;/ins&gt;SABRIL; start to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;trip&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;bump into &lt;/ins&gt;points, or are &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a lot &lt;/ins&gt;more &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;awkward &lt;/ins&gt;than &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;typical &lt;/ins&gt;[https://www.protopage.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ossidyrd9j &lt;/ins&gt;Bookmarks]; are &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;amazed &lt;/ins&gt;by individuals or points &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;coming &lt;/ins&gt;in front of you that &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;seem to find &lt;/ins&gt;out of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;no place&lt;/ins&gt;; or if your child is acting &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;differently &lt;/ins&gt;than typical.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The Vigabatrin REMS Program is required by the FDA to ensure educated risk-benefit decisions before initiating therapy, and to ensure appropriate use &lt;/ins&gt;vigabatrin &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;while clients are treated. It &lt;/ins&gt;is not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;possible for your healthcare provider &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;understand when &lt;/ins&gt;vision loss &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;will occur&lt;/ins&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;It is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;advised &lt;/ins&gt;that your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor examination &lt;/ins&gt;your (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/ins&gt;'s) vision &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;before &lt;/ins&gt;or within 4 weeks after &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;starting &lt;/ins&gt;SABRIL and at least every 3 months &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;throughout &lt;/ins&gt;therapy &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;until &lt;/ins&gt;SABRIL is stopped. If you or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kid &lt;/ins&gt;have any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;type &lt;/ins&gt;of side &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;effect &lt;/ins&gt;that &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;troubles &lt;/ins&gt;you or that does not go away, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;tell &lt;/ins&gt;your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;health care &lt;/ins&gt;provider.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell &lt;/ins&gt;your healthcare provider &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;immediately &lt;/ins&gt;if &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;seizures get worse&lt;/ins&gt;. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;You and &lt;/ins&gt;your doctor will have &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to determine if you need to take SABRIL while you are expectant. One of &lt;/ins&gt;the &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;most common side effects of SABRIL in grownups consist &lt;/ins&gt;of&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;: blurred &lt;/ins&gt;vision, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;drowsiness, wooziness, problems strolling or really feeling unskillful, drinking &lt;/ins&gt;(&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;tremor&lt;/ins&gt;)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;, and exhaustion&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>EmoryCarr4</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=157121&amp;oldid=prev</id>
		<title>MeganTraill at 15:27, 11 July 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=157121&amp;oldid=prev"/>
		<updated>2024-07-11T15:27:32Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 08:27, 11 July 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Prior to starting SABRIL, tell your medical professional regarding all of &lt;/del&gt;your (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster's&lt;/del&gt;) &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;medical problems including clinical depression&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mood problems&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;self-destructive thoughts &lt;/del&gt;[https://www.protopage.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;luanon95u5 &lt;/del&gt;Bookmarks] or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;behavior, any type &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;allergy to SABRIL, vision issues, kidney problems, reduced red cell matters (anemia), and any kind &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nervous &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;psychological illness&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;SABRIL (vigabatrin) is a prescription medicine &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;used &lt;/del&gt;with other therapies in &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;grownups &lt;/del&gt;and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;children &lt;/del&gt;2 years &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;old &lt;/del&gt;and older with refractory complicated partial seizures (CPS) &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;that &lt;/del&gt;have &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;actually &lt;/del&gt;not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;reacted &lt;/del&gt;well enough to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;numerous &lt;/del&gt;various other &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;therapies &lt;/del&gt;and if the possible benefits &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;outweigh &lt;/del&gt;the &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;danger &lt;/del&gt;of vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The most typical side effect of &lt;/del&gt;SABRIL &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;in children &lt;/del&gt;3 &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to 16 years &lt;/del&gt;is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;weight gain&lt;/del&gt;. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;With extreme vision loss, &lt;/del&gt;you &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;might just be able to see points straight in front &lt;/del&gt;of you &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;(often called one-track mind&quot;). You &lt;/del&gt;go &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to danger for vision loss with any amount of SABRIL&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If &lt;/del&gt;you are expecting or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;plan &lt;/del&gt;to obtain pregnant&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;, tell your health care provider&lt;/del&gt;. If vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;testing &lt;/del&gt;can not be done, your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider may &lt;/del&gt;proceed recommending SABRIL, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;however &lt;/del&gt;will certainly not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;be able &lt;/del&gt;to watch for any vision loss. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Your healthcare provider &lt;/del&gt;might quit &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;recommending &lt;/del&gt;SABRIL for you (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/del&gt;)&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if vision tests are not done on a regular basis&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell &lt;/ins&gt;your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider right now if you &lt;/ins&gt;(or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/ins&gt;)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;: might not be seeing as well as prior to beginning SABRIL; start to journey&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;run across points&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or are much more clumsy than usual &lt;/ins&gt;[https://www.protopage.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;farrynco6b &lt;/ins&gt;Bookmarks]&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;; are shocked by individuals &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;points being available in front &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;you that appear ahead out &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nowhere; &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if your child is acting in a different way than typical&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;SABRIL (vigabatrin) is a prescription medicine &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;utilized &lt;/ins&gt;with &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;various &lt;/ins&gt;other therapies in &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;children &lt;/ins&gt;and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;adults &lt;/ins&gt;2 years &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;of age &lt;/ins&gt;and older with refractory complicated partial seizures (CPS) &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;who &lt;/ins&gt;have not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;responded &lt;/ins&gt;well enough to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a number of &lt;/ins&gt;various other &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;treatments &lt;/ins&gt;and if the possible benefits &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;surpass &lt;/ins&gt;the &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;threat &lt;/ins&gt;of vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;It is suggested that your healthcare provider test your (or your kid's) vision prior to or within 4 weeks after beginning &lt;/ins&gt;SABRIL &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;and at the very least every &lt;/ins&gt;3 &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;months during therapy till SABRIL &lt;/ins&gt;is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;stopped&lt;/ins&gt;. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If &lt;/ins&gt;you &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or your youngster have any kind &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;side impact that bothers &lt;/ins&gt;you &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or that does not &lt;/ins&gt;go &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;away, inform your healthcare service provider&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform your healthcare provider if &lt;/ins&gt;you are expecting or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;intend &lt;/ins&gt;to obtain pregnant. If vision &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;screening &lt;/ins&gt;can not be done, your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor might &lt;/ins&gt;proceed recommending SABRIL, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;yet &lt;/ins&gt;will certainly not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;have the ability &lt;/ins&gt;to watch for any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;type of &lt;/ins&gt;vision loss. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If vision examinations are refrained from doing consistently, your doctor &lt;/ins&gt;might quit &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;suggesting &lt;/ins&gt;SABRIL for you (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/ins&gt;).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>MeganTraill</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=156096&amp;oldid=prev</id>
		<title>TabithaBrenan at 08:57, 11 July 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=156096&amp;oldid=prev"/>
		<updated>2024-07-11T08:57:31Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 01:57, 11 July 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Before beginning &lt;/del&gt;SABRIL, tell your medical professional &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;concerning every one &lt;/del&gt;of your (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/del&gt;'s) medical problems including &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;anxiety&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;state of mind issues&lt;/del&gt;, self-destructive thoughts [https://&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;atavi&lt;/del&gt;.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;share/wqj3y2zl7x02 vigabatrin rems survey&lt;/del&gt;] or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;habits&lt;/del&gt;, any type of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;allergic reaction &lt;/del&gt;to SABRIL, vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;troubles&lt;/del&gt;, kidney problems, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;low &lt;/del&gt;red &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;blood &lt;/del&gt;cell &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;counts &lt;/del&gt;(anemia), and any kind of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mental &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nervous disease&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The Vigabatrin REMS Program &lt;/del&gt;is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;required by the FDA &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ensure informed risk-benefit decisions prior to launching treatment, &lt;/del&gt;and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to make certain proper use &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;vigabatrin while individuals are treated. When &lt;/del&gt;vision loss &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;will take place, it is not possible for your medical care service provider to know&lt;/del&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;One of the &lt;/del&gt;most typical side effect of SABRIL in &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngsters &lt;/del&gt;3 to 16 years is weight gain. With extreme vision loss, you &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;may only have the ability &lt;/del&gt;to see &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;things right before &lt;/del&gt;you (&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;in some cases &lt;/del&gt;called &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;tunnel vision&lt;/del&gt;&quot;). You &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;are at threat &lt;/del&gt;for vision loss with any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;quantity &lt;/del&gt;of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell your healthcare provider if &lt;/del&gt;you are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;expectant &lt;/del&gt;or plan to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;get expectant&lt;/del&gt;. If vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;screening &lt;/del&gt;can not be done, your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor &lt;/del&gt;may proceed recommending SABRIL, however will certainly not be able to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;look &lt;/del&gt;for any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kind of &lt;/del&gt;vision loss. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If vision examinations are refrained from doing consistently, your doctor may &lt;/del&gt;quit &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;suggesting &lt;/del&gt;SABRIL for you (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/del&gt;).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Prior to starting &lt;/ins&gt;SABRIL, tell your medical professional &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;regarding all &lt;/ins&gt;of your (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/ins&gt;'s) medical problems including &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;clinical depression&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mood problems&lt;/ins&gt;, self-destructive thoughts [https://&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;www.protopage&lt;/ins&gt;.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;luanon95u5 Bookmarks&lt;/ins&gt;] or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;behavior&lt;/ins&gt;, any type of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;allergy &lt;/ins&gt;to SABRIL, vision &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;issues&lt;/ins&gt;, kidney problems, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;reduced &lt;/ins&gt;red cell &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;matters &lt;/ins&gt;(anemia), and any kind of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nervous &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;psychological illness&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SABRIL (vigabatrin) &lt;/ins&gt;is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a prescription medicine used with other therapies in grownups and children 2 years old and older with refractory complicated partial seizures (CPS) that have actually not reacted well enough &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;numerous various other therapies &lt;/ins&gt;and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if the possible benefits outweigh the danger &lt;/ins&gt;of vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The &lt;/ins&gt;most typical side effect of SABRIL in &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;children &lt;/ins&gt;3 to 16 years is weight gain. With extreme vision loss, you &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;might just be able &lt;/ins&gt;to see &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;points straight in front of &lt;/ins&gt;you (&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;often &lt;/ins&gt;called &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;one-track mind&lt;/ins&gt;&quot;). You &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;go to danger &lt;/ins&gt;for vision loss with any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;amount &lt;/ins&gt;of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If &lt;/ins&gt;you are &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;expecting &lt;/ins&gt;or plan to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;obtain pregnant, tell your health care provider&lt;/ins&gt;. If vision &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;testing &lt;/ins&gt;can not be done, your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider &lt;/ins&gt;may proceed recommending SABRIL, however will certainly not be able to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;watch &lt;/ins&gt;for any vision loss. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Your healthcare provider might &lt;/ins&gt;quit &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;recommending &lt;/ins&gt;SABRIL for you (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/ins&gt;)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if vision tests are not done on a regular basis&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>TabithaBrenan</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=154877&amp;oldid=prev</id>
		<title>JovitaHan21 at 03:19, 11 July 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=154877&amp;oldid=prev"/>
		<updated>2024-07-11T03:19:25Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 20:19, 10 July 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform &lt;/del&gt;your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor immediately if you &lt;/del&gt;(or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/del&gt;)&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;: may not be viewing as well as before starting SABRIL; start to journey&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;run across points&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or are a lot more awkward than typical &lt;/del&gt;[https://&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;www.symbaloo&lt;/del&gt;.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;embed/shared&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;AAAAA5hXUmUAA41_WsxdaA== &lt;/del&gt;vigabatrin &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;side effects drowsiness&lt;/del&gt;]&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;; are stunned by things &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;people being available in front &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;you that seem ahead out &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nowhere; &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if your baby is acting differently than normal&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The Vigabatrin REMS Program is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;called for &lt;/del&gt;by the FDA to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;guarantee notified &lt;/del&gt;risk-benefit &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;choices before &lt;/del&gt;launching &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;therapy&lt;/del&gt;, and to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ensure &lt;/del&gt;proper use of vigabatrin while &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;people &lt;/del&gt;are &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;dealt with&lt;/del&gt;. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;It &lt;/del&gt;is not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;feasible &lt;/del&gt;for your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;understand when vision loss will take place&lt;/del&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;One of the most &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;common &lt;/del&gt;side effect of SABRIL in &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;children &lt;/del&gt;3 to 16 years is weight gain. With extreme vision loss, you may &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;just &lt;/del&gt;have the ability to see things &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;directly &lt;/del&gt;before you (&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;sometimes &lt;/del&gt;called tunnel vision&quot;). You are at &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;risk &lt;/del&gt;for vision loss with any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;amount &lt;/del&gt;of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Tell your healthcare provider if you are expectant or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mean &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;obtain expecting&lt;/del&gt;. If vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;testing &lt;/del&gt;can not be done, your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider &lt;/del&gt;may proceed recommending SABRIL, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;but &lt;/del&gt;will certainly not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;have the ability &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;expect &lt;/del&gt;any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;type &lt;/del&gt;of vision loss. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Your healthcare supplier might &lt;/del&gt;quit &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;prescribing &lt;/del&gt;SABRIL for you (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kid&lt;/del&gt;)&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if vision tests are not done consistently&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Before beginning SABRIL, tell your medical professional concerning every one of &lt;/ins&gt;your (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child's&lt;/ins&gt;) &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;medical problems including anxiety&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;state of mind issues&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;self-destructive thoughts &lt;/ins&gt;[https://&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;atavi&lt;/ins&gt;.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;share&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;wqj3y2zl7x02 &lt;/ins&gt;vigabatrin &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rems survey&lt;/ins&gt;] or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;habits, any type &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;allergic reaction to SABRIL, vision troubles, kidney problems, low red blood cell counts (anemia), and any kind &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mental &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nervous disease&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The Vigabatrin REMS Program is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;required &lt;/ins&gt;by the FDA to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;ensure informed &lt;/ins&gt;risk-benefit &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;decisions prior to &lt;/ins&gt;launching &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;treatment&lt;/ins&gt;, and to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;make certain &lt;/ins&gt;proper use of vigabatrin while &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;individuals &lt;/ins&gt;are &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;treated&lt;/ins&gt;. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;When vision loss will take place, it &lt;/ins&gt;is not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;possible &lt;/ins&gt;for your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;medical care service provider &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;know&lt;/ins&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;One of the most &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;typical &lt;/ins&gt;side effect of SABRIL in &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngsters &lt;/ins&gt;3 to 16 years is weight gain. With extreme vision loss, you may &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;only &lt;/ins&gt;have the ability to see things &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;right &lt;/ins&gt;before you (&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;in some cases &lt;/ins&gt;called tunnel vision&quot;). You are at &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;threat &lt;/ins&gt;for vision loss with any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;quantity &lt;/ins&gt;of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Tell your healthcare provider if you are expectant or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;plan &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;get expectant&lt;/ins&gt;. If vision &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;screening &lt;/ins&gt;can not be done, your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor &lt;/ins&gt;may proceed recommending SABRIL, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;however &lt;/ins&gt;will certainly not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;be able &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;look for &lt;/ins&gt;any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kind &lt;/ins&gt;of vision loss. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If vision examinations are refrained from doing consistently, your doctor may &lt;/ins&gt;quit &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;suggesting &lt;/ins&gt;SABRIL for you (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/ins&gt;).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>JovitaHan21</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=154544&amp;oldid=prev</id>
		<title>NellyCrenshaw at 02:58, 11 July 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=154544&amp;oldid=prev"/>
		<updated>2024-07-11T02:58:10Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 19:58, 10 July 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Before beginning SABRIL, tell your physician concerning all of &lt;/del&gt;your (or your youngster&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'s&lt;/del&gt;) &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;clinical problems including depression&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mood troubles&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;self-destructive ideas &lt;/del&gt;[https://&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;atavi&lt;/del&gt;.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;share&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;wpqxsuzjtief &lt;/del&gt;vigabatrin &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rems patient enrollment form&lt;/del&gt;] or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;actions, any type &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;allergy to SABRIL, vision troubles, kidney problems, low red blood cell matters (anemia), and any kind &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nervous &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;psychological ailment&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SABRIL (vigabatrin) &lt;/del&gt;is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a prescription medicine utilized with various other treatments in kids &lt;/del&gt;and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;grownups 2 years &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;age and older &lt;/del&gt;with &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;refractory facility partial seizures (CPS) who have &lt;/del&gt;not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;responded all right &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a number of other treatments and if the feasible advantages outweigh the danger of &lt;/del&gt;vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The &lt;/del&gt;most &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;usual adverse effects &lt;/del&gt;of SABRIL in &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kids &lt;/del&gt;3 to 16 years is weight gain. With &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;severe &lt;/del&gt;vision loss, you may &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;only be able &lt;/del&gt;to see &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;points right in front of &lt;/del&gt;you (&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;often &lt;/del&gt;called &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;one-track mind&lt;/del&gt;&quot;). You are at &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;threat &lt;/del&gt;for vision loss with any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;quantity &lt;/del&gt;of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If seizures obtain worse, tell &lt;/del&gt;your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;medical care service &lt;/del&gt;provider &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;right away&lt;/del&gt;. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;You and &lt;/del&gt;your healthcare provider will certainly &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;need &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;decide if you ought to take &lt;/del&gt;SABRIL &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;while &lt;/del&gt;you &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;are expecting. The most common side effects of SABRIL in grownups include: obscured vision, drowsiness, dizziness, problems strolling &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;feeling unskillful, shaking (tremor&lt;/del&gt;)&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;, and fatigue&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform &lt;/ins&gt;your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doctor immediately if you &lt;/ins&gt;(or your youngster)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;: may not be viewing as well as before starting SABRIL; start to journey&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;run across points&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or are a lot more awkward than typical &lt;/ins&gt;[https://&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;www.symbaloo&lt;/ins&gt;.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;embed&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;shared/AAAAA5hXUmUAA41_WsxdaA== &lt;/ins&gt;vigabatrin &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;side effects drowsiness&lt;/ins&gt;]&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;; are stunned by things &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;people being available in front &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;you that seem ahead out &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nowhere; &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if your baby is acting differently than normal&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The Vigabatrin REMS Program &lt;/ins&gt;is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;called for by the FDA to guarantee notified risk-benefit choices before launching therapy, &lt;/ins&gt;and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;to ensure proper use &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;vigabatrin while people are dealt &lt;/ins&gt;with&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;. It is &lt;/ins&gt;not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;feasible for your doctor &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;understand when &lt;/ins&gt;vision loss &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;will take place&lt;/ins&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;One of the &lt;/ins&gt;most &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;common side effect &lt;/ins&gt;of SABRIL in &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;children &lt;/ins&gt;3 to 16 years is weight gain. With &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;extreme &lt;/ins&gt;vision loss, you may &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;just have the ability &lt;/ins&gt;to see &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;things directly before &lt;/ins&gt;you (&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;sometimes &lt;/ins&gt;called &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;tunnel vision&lt;/ins&gt;&quot;). You are at &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;risk &lt;/ins&gt;for vision loss with any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;amount &lt;/ins&gt;of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell &lt;/ins&gt;your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare &lt;/ins&gt;provider &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if you are expectant or mean to obtain expecting&lt;/ins&gt;. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If vision testing can not be done, &lt;/ins&gt;your healthcare provider &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;may proceed recommending SABRIL, but &lt;/ins&gt;will certainly &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;not have the ability &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;expect any type of vision loss. Your healthcare supplier might quit prescribing &lt;/ins&gt;SABRIL &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;for &lt;/ins&gt;you &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;(&lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;your kid&lt;/ins&gt;)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if vision tests are not done consistently&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>NellyCrenshaw</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=82274&amp;oldid=prev</id>
		<title>BonniePrins38: Created page with &quot;Before beginning SABRIL, tell your physician concerning all of your (or your youngster's) clinical problems including depression, mood troubles, self-destructive ideas [https://atavi.com/share/wpqxsuzjtief vigabatrin rems patient enrollment form] or actions, any type of allergy to SABRIL, vision troubles, kidney problems, low red blood cell matters (anemia), and any kind of nervous or psychological ailment.&lt;br&gt;&lt;br&gt;SABRIL (vigabatrin) is a prescription medicine utilized w...&quot;</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=MedlinePlus_Drug_Information.&amp;diff=82274&amp;oldid=prev"/>
		<updated>2024-06-27T14:57:51Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;Before beginning SABRIL, tell your physician concerning all of your (or your youngster&amp;#039;s) clinical problems including depression, mood troubles, self-destructive ideas [https://atavi.com/share/wpqxsuzjtief vigabatrin rems patient enrollment form] or actions, any type of allergy to SABRIL, vision troubles, kidney problems, low red blood cell matters (anemia), and any kind of nervous or psychological ailment.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;SABRIL (vigabatrin) is a prescription medicine utilized w...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Before beginning SABRIL, tell your physician concerning all of your (or your youngster's) clinical problems including depression, mood troubles, self-destructive ideas [https://atavi.com/share/wpqxsuzjtief vigabatrin rems patient enrollment form] or actions, any type of allergy to SABRIL, vision troubles, kidney problems, low red blood cell matters (anemia), and any kind of nervous or psychological ailment.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;SABRIL (vigabatrin) is a prescription medicine utilized with various other treatments in kids and grownups 2 years of age and older with refractory facility partial seizures (CPS) who have not responded all right to a number of other treatments and if the feasible advantages outweigh the danger of vision loss. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The most usual adverse effects of SABRIL in kids 3 to 16 years is weight gain. With severe vision loss, you may only be able to see points right in front of you (often called one-track mind&amp;quot;). You are at threat for vision loss with any quantity of SABRIL.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;If seizures obtain worse, tell your medical care service provider right away. You and your healthcare provider will certainly need to decide if you ought to take SABRIL while you are expecting. The most common side effects of SABRIL in grownups include: obscured vision, drowsiness, dizziness, problems strolling or feeling unskillful, shaking (tremor), and fatigue.&lt;/div&gt;</summary>
		<author><name>BonniePrins38</name></author>
	</entry>
</feed>